High percentage of rheumatoid arthritis patients discontinue triple therapy, adding or substituting other drugs after two years

A high percentage of rheumatoid arthritis patients discontinue triple therapy, a combination of disease-modifying antirheumatic drugs, after one to two years, according to new research.